Polycystic kidney disease: New horizons and therapeutic frontiers

Minerva Urologica e Nefrologica

Volumn 65, Issue 1, 2013, Pages 61-68

  Czarnecki, P G ^a   Steinman, T I ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Biological markers; Polycystic kidney, autosomal dominant; Therapeutics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; KD 019; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL] 2 BUTYNAMIDE; OCTREOTIDE; PELITINIB; PLACEBO; POLYCYSTIN 1; POLYCYSTIN 2; PYRIMETHAMINE; RAPAMYCIN; ROSCOVITINE; STAT3 PROTEIN; STAT6 PROTEIN; TOLVAPTAN; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG;

ACNE; ANEMIA; APHTHOUS STOMATITIS; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DIARRHEA; DISEASE COURSE; DRUG SAFETY; GENE MUTATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; INTRACELLULAR SIGNALING; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT RESPONSE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY FAILURE, CHRONIC; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PREVALENCE; PROTEIN KINASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIGNAL TRANSDUCTION; TRPP CATION CHANNELS;

EID: 84878762275     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007;369:1287-301. (Pubitemid 46552051)
2. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 2009;60:321-37.
3. Corradi V, Gastaldon F, Virzì GM, Clementi M, Nalesso F, Cruz DN et al. Epidemiological and molecular study of autosomal dominant polycystic kidney disease (ADPKD) in the province of Vicenza, Italy: possible founder effect? G Ital Nefrol 2010;27:655-63.
4. Pazour GJ. Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease. J Am Soc Nephrol 2004;15:2528-36. (Pubitemid 41103359)
5. Hughes J, Ward CJ, Peral B, Aspinwall R, Clark K, San Millán JL et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet 1995;10:151-60.
6. [No authors listed]. The International Polycystic Kidney Disease Consortium "Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 1995;81:289-98.
7. Tsiokas L, Kim E, Arnould T, Sukhatme VP, Walz G. Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc Natl Acad Sci U S A 1997;94:6965-70. (Pubitemid 27281974)
8. Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ et al. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996;272:1339-42. (Pubitemid 26199975)
9. González-Perrett S, Kim K, Ibarra C, Damiano AE, Zotta E, Batelli M et at. Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel. Proc Natl Acad Sci U S A 2001;98:1182-7. (Pubitemid 32121207)
10. Koulen P, Cai Y, Geng L, Maeda Y, Nishimura S, Witzgall R et al. Polycystin-2 is an intracellular calcium release channel. Nat Cell Biol 2002;4:191-7. (Pubitemid 34218192)
11. Pazour GJ, San Agustin JT, Follit JA, Rosenbaum JL, Witman GB. Polycystin-2 localizes to kidney cilia and the ciliary level is elevated in orpk mice with polycystic kidney disease. Curr Biol 2002;12:R378-80. (Pubitemid 34689219)
12. Yoder BK, Hou X, Guay-Woodford LM. The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia. J Am Soc Nephrol 2002;13:2508-16.
13. Nauli SM, Alenghat FJ, Luo Y, Williams E, Vassilev P, Li X et al. Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells. Nat Genet 2003;33:129-37. (Pubitemid 36177063)
14. Wang S, Zhang J, Nauli SM, Li X, Starremans PG, Luo Y, Roberts KA et al. Fibrocystin/polyductin, found in the same protein complex with polycystin-2, regulates calcium responses in kidney epithelia. Mol Cell Biol 2007;27:3241-52. (Pubitemid 46581334)
15. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 2004;279:40419-30. (Pubitemid 39287631)
16. Davidow CJ, Maser RL, Rome LA, Calvet JP, Grantham JJ. The cystic fibrosis transmembrane conductance regulator mediates transepithelial fluid secretion by human autosomal dominant polycystic kidney disease epithelium in vitro. Kidney Int 1996;50:208-18. (Pubitemid 26323715)
17. Talbot JJ, Shillingford JM, Vasanth S, Doerr N, Mukherjee S, Kinter MT et al. Polycystin-1 regulates STAT activity by a dual mechanism. Proc Natl Acad Sci U S A. 2011;108:7985-90.
18. Low SH, Vasanth S, Larson CH, Mukherjee S, Sharma N, Kinter MT et at. Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. Dev Cell 2006;10:57-69. (Pubitemid 43025677)
19. Ibraghimov-Beskrovnaya O, Natoli TA. mTOR signaling in polycystic kidney disease. Trends Mol Med 2011;17:625-33.
20. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, Brown N et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 2006;103:5466-71.
21. Dere R, Wilson PD, Sandford RN, Walker CL. Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR. PLoS One 2010;5:e9239.
22. Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, Piontek KB et al. Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 2009;29:2359-71.
23. Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, Everitt J, Xu H, Kiguchi K et al. Tuberin-dependent membrane localization of polycystin-1: a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol Cell 2001;7:823-32. (Pubitemid 32436442)
24. Boehlke C, Kotsis F, Patel V, Braeg S, Voelker H, Bredt S et al. Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat Cell Biol 2010;12:1115-22.
25. Simons M, Gloy J, Gartner A, Bullerkotte A, Bashkurov M, Krönig C et al. Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat Genet 2005;37:537-43.
26. Czarnecki PG, Shah JV. The ciliary transition zone: from morphology and molecules to medicine. Trends Cell Biol 2012;22:201-10.
27. Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr et at. CRISP Investigators: Volume Progression In Polycystic Kidney Disease. N Engl J Med 2006;354:2122-30. (Pubitemid 43736612)
28. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006;1:148-57.
29. Huber TB, Walz G, Kuehn EW. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 2011;79:502-11.
30. Moreno S, Ibraghimov-Beskrovnaya O, Bukanov NO. Serum and urinary biomarker signatures for rapid preclinical in vivo assessment of CDK inhibition as a therapeutic approach for PKD. Cell Cycle 2008;7:1856-64. (Pubitemid 351988752)
31. Mosley K, Tam FW, Edwards RJ, Crozier J, Pusey CD, Lightstone L. Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology (Oxford) 2006;45:1497-504. (Pubitemid 44817055)
32. Nguyen MT, Ross GF, Dent CL, Devarajan P. Early prediction of acute renal injury using urinary proteomics. Am J Nephrol 2005;25:318-26. (Pubitemid 41160990)
33. Schaub S, Rush D, Wilkins J, Gibson IW, Weiler T, Sangster K et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004;15:219-27. (Pubitemid 38020714)
34. USDA. Develop biomarkers to aid in the development of therapies for polycystic kidney disease (PKD). In Key FDA critical path activities under way in 2007. Washington, D.C.: U.S. Department of Health and Human Services Food and Drug Administration; June 2008. p. 5.
35. Meijer E, Rook M, Tent H, Navis G, van der Jagt EJ, de Jong PE et al. Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010;5:1091-8.
36. Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med 2008;359:1477-85.
37. Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller DC et al. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 2010;5:102-9.
38. Leuenroth SJ, Okuhara D, Shotwell JD, Markowitz GS, Yu Z, SomLo S et al. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci U S A 2007;104:4389-94. (Pubitemid 47186236)
39. Leuenroth SJ, Bencivenga N, Igarashi P, SomLo S, Crews CM. Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol 2008;19:1659-62.
40. Leuenroth SJ, Bencivenga N, Chahboune H, Hyder F, Crews CM. Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD. Nephrol Dial Transplant 2010;25:2187-94.
41. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008;19:102-8.
42. Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003;9:1323-6. (Pubitemid 37279858)
43. Torres VE, Meijer E, Bae KT, Chapman AB, Devuyst O, Gansevoort RT et al. "Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Am J Kidney Dis 2011;57:692-9.
44. Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ et al. TEMPOFormula and 156-05-002 Study Investigators: Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience. Clin J Am Soc Nephrol 2011;6:2499-507.
45. Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG et al. Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 2011;80:295-301.
46. Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 2009;4:1140-50.
47. Barash I, Ponda MP, Goldfarb DS, Skolnik EY. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010;5:693-7.
48. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005;68:206-16. (Pubitemid 43181378)
49. Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 2010;21:1052-61.
50. Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M et al. Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 2010;21:1031-40.
51. Walz G, Budde K, Mannaa M, Nürnberger J, Wanner C, Sommerer C et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2010;363.830-40.
52. Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 2010;363.820-9.
53. Torres VE, Boletta A, Chapman A, Gattone V, Pei Y, Qian Q et al. Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases. Clin J Am Soc Nephrol 2010;5:1312-29.
54. Takiar V, Nishio S, Seo-Mayer P, King JD Jr, Li H, Zhang L et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A 2011;108:2462-7.
55. Yang B, Sonawane ND, Zhao D, SomLo S, Verkman AS. Small-molecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol 2008;19:1300-10.
56. Bukanov NO, Smith LA, Klinger KW, Ledbetter SR, Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006;444:949-52. (Pubitemid 46025010)
57. Leonhard WN, van der Wal A, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH et al. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol 2011;300:F1193-202.
58. Takakura A, Nelson EA, Haque N, Humphreys BD, Zandi-Nejad K, Frank DA et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum Mol Genet 2011;20:4143-54.